The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database

Christos Bakirtzis1†, Eleni Grigoriadou1†, Marina Kleopatra Boziki1, Evangelia Kesidou1, Spyridon Siafas2,3, Theodoros Moysiadi4, Dimitra Tsakona4, Eleftherios Thireos4, Ioannis Nikolaidis1, Chrysa Pourzitaki2, Dimitrios Kouvelas2, Georgios Papazisis2, Dimitrios Tsalikakis6 and Nikolaos Grigoriadis1*

1 Multiple Sclerosis Center, B’ Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece, 2 Department of Clinical Pharmacology, Aristotle University of Thessaloniki, Thessaloniki, Greece, 3 Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany, 4 Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece, 5 Athens Medical Society, Athens, Greece, 6 Department of Informatics and Telecommunications Engineering, University of Western Macedonia, Kozani, Greece

Objective: To estimate current prevalence of multiple sclerosis (MS) in Greece using administrative data from the nationwide medicine prescription database.

Methods: Prescription records of a 24-month period (June 2017–May 2019) were analyzed in order to identify cases of MS. Sex, age, and place of residence were recorded for each identified case. Prevalence of MS was calculated based on the updated records of the Greek population according to Hellenic Statistical Authority.

Results: The 2-year cumulative period prevalence of MS was estimated to 197.8 per 100,000 (95% CI 197.6–198.0). In total, 21,218 patients (65.8% female) were identified. During this period, the prevalence of MS was 138.7 per 100,000 (95% CI 138.4–139.0) in men and 253.6 per 100,000 (95% CI 253.3–254.1) in women. Prevalence was higher in the 45–49 age group in both sexes. Analysis of the place of residence revealed higher prevalence in the Attica region and Western Greece while lower prevalence was observed in Northern Greece. No north–south latitude gradient was detected. Point prevalence on 1 January 2019 was calculated to 188.9 per 100,000 (95% CI 188.7–189.1). Regarding treatment, 73.1% of the identified cases received at least once a Disease Modifying Drug.

Conclusions: According to this national-level study conducted in Greece, estimated prevalence of MS was found to be similar to those of other European countries. Heterogeneity of MS prevalence across the country was observed and needs further investigation.

Keywords: prevalence, multiple sclerosis, Greece, epidemiology, prescription

INTRODUCTION

Multiple sclerosis (MS) is a chronic autoimmune and neurodegenerative disease that affects about 2.3 million people worldwide (1). This chronic disease is one of the most common causes of disability in young populations (2). In Europe, prevalence of MS is rising (3); however, geographical variations may be observed (4, 5). It remains unclear whether this heterogeneity can be...
attributed exclusively to genetic and environmental factors, since access to healthcare and insurance policies varies across countries and may influence the results of prevalence studies performed on this continent.

In Greece, epidemiological data regarding MS are scarce; however, a number of previous studies have suggested an increment of prevalence from 10.2 per 100,000 in 1984 (6), to 29.5 per 100,000 in 1990 (7), 38.9 per 100,000 in 1999 (8), and more than 100 per 100,000 according to two studies performed in 2006 and in 2008 respectively (9, 10). All relevant studies were regional and applied various diagnostic criteria (Table 1). Regarding annual incidence rate, an increase from 2.71/100,000 in 1989 to 10.73/100,000 in 2006 has been reported by one study (9), while another one demonstrated the rise of incidence rates in the urban areas of the island of Crete, located in south Greece, from 2.1 per 100,000 in 1984, to 7 per 100,000 in 2008 (10). As of 2008, no new epidemiological data for Greek people with MS exist.

According to the Atlas of MS (1), last updated in 2013, Greece belongs to the group of countries presenting prevalence of the disease somewhere between 60 and 100 per 100,000; this information may be outdated, though. Since the landscape of MS diagnosis and treatment is rapidly evolving, newer national-level prevalence studies are needed in order to accurately calculate prevalence of the disease (4). Patient registries and health claims data may therefore be used in order to estimate the prevalence of the disease within a country (11, 12). Although these administrative data are primarily collected for reimbursement, they may also be used for epidemiological studies, since they are uniformly collected and represent a large amount of the population studied (13).

In the absence of a nationwide registry for people with MS (PwMS), we aimed to estimate current prevalence of MS in Greece using data from the nationwide prescription database. This study was performed after permission for use of pseudoanonymized and coded prescription data by IDIKA S.A.1, a non-profit government organization responsible for the digital health data in Greece, in accordance with the national legislations on personal data and with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

**METHODS**

Greece is a European country that lies in the Eastern Mediterranean Sea. The country's territory includes 132,049 Km² located between 34.8° and 41.7° N latitudes and 19.3° and 29.6° W longitudes. The country's population is estimated to 10,724,599 on 1 January 2019, according to Hellenic Statistical Authority (ELSTAT), which is the national statistical service 2.

Currently, diagnosis of MS in Greece is based on McDonald criteria and their revisions (14), according to the guidelines of Hellenic Academy of Neuroimmunology (HELANI), which have been adopted by the Greek Ministry of Health (15). Up to now, disease modifying drugs (DMDs) are fully reimbursed (100%) to all Greek people with MS (PwMS). Some agents for symptomatic treatment such as baclofen and fampridine are also fully covered (100%), whereas others are partially reimbursed (90 or 75%, depending on the substance). The National Organization for the Provision of Health Services (EOPYY) is the largest national health-care provider 3, reimbursing health expenses for almost the entire Greek population. Medical expenses of ~200,000–300,000 citizens (mainly permanent military personnel, their family members, and people without social security number) are reimbursed by authorities other than EOPYY, thus corresponding to ~1.8–2.7% of the Greek population 1,4. EOPYY reimburses drug prescriptions that are performed through a nationwide digital medicine prescription database 5, which runs under surveillance of IDIKA S.A., on behalf of the Greek Ministry of Health. All prescriptions are registered under the International Classification of Diseases v. 10 (ICD-10) coding system. The code G35 is assigned to MS. This code is used by all clinicians in order to prescribe DMDs and agents for MS symptomatic treatment in Greece, whereas an additional medical report, signed by the treating physician, is also mandatory and a prerequisite for the processing of each prescription. Information such as type of MS, disease duration, and EDSS were not included in this prescription database during the study period. Therefore, the IDIKA S.A. prescription database may currently not regarded as an MS disease registry. Such national MS disease registry is currently under construction and is expected to include thorough information regarding clinical and laboratory disease parameters.

Two independent researchers analyzed prescription data from the nationwide prescription database of IDIKA S.A., dating from June 1, 2017, to May 31, 2019, and identified MS cases using the ICD-10 code for MS (G35). Criterion for the case identification was ≥1 MS specific drug prescription (DMD or symptomatic) in this 24-month period and the analysis was performed on the basis of the active substances. Prescriptions not executed in pharmacies were excluded from the study analysis. We then extracted data regarding age, sex, and place of residence for each individual case. All discrepancies between the two independent analyses were reviewed on a case by case basis. Finally, a third researcher validated the results by conducting a third blinded analysis. In addition, the most recent data derived from ELSTAT, regarding Greek population, were used. In brief, current Greek population was calculated based on the population census of 2011 adjusted to January 1, 2019, according to birth and death records as well as official immigration data. Finally, age, sex, and regional prevalence of the disease were calculated.

In order to explore the potential contribution of a north–south latitude gradient, the latitudinal coordinates of each region were used. After examining for normality, prevalence rates of each region were compared with the corresponding latitudes using Pearson’s correlation. Level of significance was set at \( p < 0.05 \).

---

1. http://www.idika.gr
2. Hellenic Statistical Authority. Available online at https://www.statistics.gr
3. www.eopyy.gov.gr
4. https://www.nato.int/nato_static_fl2014/assets/pdf/pdf_2019_06/20190625_PR2019-069-EN.pdf
5. https://www.e-prescription.gr
TABLE 1 | Previous studies regarding prevalence of multiple sclerosis in Greece.

| Study                      | Region         | Prevalence (/100,000) | Source of medical records | Range of years | Methodology used                  | Diagnostic criteria      |
|----------------------------|----------------|-----------------------|---------------------------|----------------|-----------------------------------|--------------------------|
| Vasilopoulos (6)           | Attica         | 10.2                  | 1 clinic                  | 1964–1983      | Extrapolation according to ALS global prevalence | Not mentioned            |
| Mionas et al. (7)          | Northern Greece| 29.5                  | 4 clinics and 18 private offices | 1970–1984      | Point prevalence on 31 December 1984 | Poser                    |
| Piperidou et al. (8)       | Eves           | 38.9                  | 1 clinic                  | 1974–1999      | Point prevalence on 31 December 1999 | Poser                    |
| Papathanasopoulos et al. (9)| Western Greece | 119.6                 | 1 clinic                  | 1984–2006      | Point prevalence on 31 December 2006 | Poser and McDonald       |
| Kotzamani et al. (10)      | Crete          | 108                   | All neurologists of Crete | 1980–2008      | Point prevalence on 31 December 2008 | McDonald                 |

Statistical analysis was performed using IBM® SPSS software 25.0 (Armonk, NY).

RESULTS

According to our study results, 21,218 (13,994 or 65.8% females, sex ratio 1.93:1) individual cases of MS were identified. Mean age of the PwMS was 46.6 ± 13.5 (range 8–95; Figure 1). The 2-year period prevalence was 138.7 per 100,000 males (95% CI 138.4–139.0) and 253.6 per 100,000 for females (95% CI 253.3–254.1). Overall, 2-year period prevalence was calculated to 197.8 per 100,000 (95% CI 197.6–198.0). Higher prevalence was calculated in the 45–49 age group (371.3 per 100,000, 95% CI 370.2–372.4) for both males (250.5 per 100,000, 95% CI 249.1–251.9) and females (486.7 per 100,000, 95% CI 485.3–488.3; Table 2). Cases with age under 18 (n = 133, 81 or 60.9% females) accounted for 0.6% of the total identified MS cases. The estimated point prevalence on January 1, 2019, was 188.9 per 100,000 (95% CI 188.7–189.1). The higher prevalence rates were observed in Attica region (263.6 per 100,000, 95% CI 263.2–264.0) followed by regions of Western Greece, while the region of Rodopi in northern Greece presented the lowest prevalence rates (84.0
## Table 2: Two-year period administrative prevalence of multiple sclerosis according to age and sex.

| Age group | Male PwMS | Male population (/100,000) | 95% CI | Female PwMS | Female population (/100,000) | 95% CI | Total PwMS | Total population | Prevalence (/100,000) | 95% CI |
|-----------|-----------|---------------------------|--------|-------------|-------------------------------|--------|-------------|-----------------|----------------------|--------|
| 0–4       | 0         | 2.39,732                  | 0      | 0           | 2.26,944                     | 0      | 0           | 4.66,676        | 0                    | –      |
| 5–9       | 2         | 2.71,053                  | 0.7    | 2           | 2.56,980                     | 0.3    | 3           | 5.28,033        | 0.5                  | [0.5–0.5] |
| 10–14     | 16        | 2.78,937                  | 5.7    | 21          | 2.63,429                     | 7.9    | 37          | 5.42,386        | 6.8                  | [6.6–7.0] |
| 15–19     | 91        | 2.83,450                  | 32.1   | 148         | 2.62,687                     | 56.3   | 239         | 5.46,137        | 43.7                 | [43.3–44.3] |
| 20–24     | 265       | 2.86,472                  | 92.5   | 437         | 2.65,850                     | 164.3  | 702         | 5.52,322        | 127.0                | [126.2–128.0] |
| 25–29     | 415       | 2.89,329                  | 143.4  | 850         | 2.79,643                     | 303.9  | 1,265       | 5.68,972        | 222.3                | [221.2–223.4] |
| 30–34     | 638       | 3.04,326                  | 209.6  | 1,228       | 3.05,389                     | 402.1  | 1,866       | 6.09,715        | 306.0                | [304.8–307.2] |
| 35–39     | 870       | 3.83,663                  | 226.7  | 1,754       | 3.82,507                     | 458.5  | 2,624       | 7.66,170        | 342.4                | [341.4–343.6] |
| 40–44     | 952       | 3.97,530                  | 239.4  | 1,894       | 4.04,656                     | 468.0  | 2,846       | 8.02,186        | 354.7                | [353.8–355.8] |
| 45–49     | 987       | 3.93,951                  | 250.5  | 2,006       | 4.12,102                     | 486.7  | 2,993       | 8.06,053        | 371.3                | [370.2–372.4] |
| 50–54     | 916       | 3.76,235                  | 243.4  | 1,755       | 4.05,972                     | 432.2  | 2,671       | 7.82,207        | 341.4                | [340.4–341.5] |
| 55–59     | 774       | 3.38,020                  | 228.9  | 1,494       | 3.80,563                     | 392.5  | 2,268       | 7.18,583        | 315.6                | [314.5–316.7] |
| 60–64     | 549       | 3.16,380                  | 173.5  | 1,067       | 3.55,526                     | 300.1  | 1,616       | 6.71,906        | 240.5                | [239.5–241.5] |
| 65–69     | 352       | 2.85,694                  | 123.2  | 648         | 3.21,158                     | 201.7  | 1,000       | 6.06,852        | 164.7                | [163.9–165.7] |
| 70–74     | 207       | 2.55,713                  | 80.9   | 372         | 3.01,680                     | 123.3  | 579         | 5.57,393        | 103.8                | [103.1–104.7] |
| 90–94     | 4         | 36,371                    | 10.9   | 8           | 56.301                       | 14.2   | 12          | 92.672          | 12.9                 | [12.2–13.6] |
| 95–99     | 0         | 10,028                    | 0      | 1           | 12,997                       | 7.6    | 1           | 23,025          | 4.3                  | [3.5–5.2] |
| Total     | 7,224     | 52,08,293                 | 138.7  | 13994       | 55,16,306                    | 253.6  | 21,218      | 107,245,99      | 197.8                | [197.6–198.0] |

PwMS, people with multiple sclerosis; age is indicated in years.
Prevalence of MS is increasing worldwide (16). This phenomenon may be attributed to improved access to health professionals and magnetic resonance imaging (17). In addition, current diagnostic criteria enable an earlier diagnosis of the disease (18, 19). Early treatment initiation is suggested to improve long-term disability outcomes and potentially affect mortality due to MS related complications (20, 21).

According to our study results and previous epidemiological ones, prevalence of MS in Greece has substantially increased within a decade. This might be due to increased access to healthcare professionals; Greece presents one of the highest rates of physicians per population (6.3 per 1,000 people in 2013) (22). Moreover, nowadays, uninsured PwMS have unrestricted access to a public healthcare system and DMDs, and therefore they can be recorded in the digital prescription database of IDIKAS.A. In addition, MS patient organizations may also have contributed to the raising of public awareness regarding the disease, by actively organizing events during the last years.

Although sex ratio in this study was in accordance with international studies regarding MS (16), a latitudinal gradient was not detected, though, heterogeneity between regions was observed. Attica prefecture exhibits the higher prevalence of PwMS (263 per 100,000). Athens, which is the capital and largest city in Greece, is located in Attica. Previous studies have suggested that MS prevalence is higher in urban areas, especially in large cities (15, 23, 24). Whether risk factors associated with urbanization, such as air pollution and/or more direct access to specialized healthcare, contribute to these results remains to be elucidated (25). High prevalence rates were also calculated for Western Greece, while lower prevalence rates were exhibited in Northern Greece. The existence of environmental or other risk factors in these areas should further be explored. Study results are in accordance with current literature suggesting no obvious north–south gradient of MS prevalence within a country (26, 27). This might be due to the limited latitude extent of Greece and other studied countries. In addition, in western countries, latitudinal difference may not be observed perhaps due to the reported homogenization of lifestyle habits (28).

For both sexes, higher prevalence was calculated in the 45–49 age group. These results are in accordance to other studies that report similar age distribution among PwMS (24, 29–33). Moreover, change in age distribution over time toward gradually increasing age at prevalence peak has been proposed as an indicator of reduced mortality for PwMS (29). The present study provides a cross-sectional estimation of MS prevalence in Greece.
based on a 2-year period and does not include consecutive estimations of MS prevalence over several decades. Therefore, this study could not explore changes in age distribution over time. However, by taking into account overall improvements in parameters of quality of life and access to health services and DMDs in Greece over the last decades, it is likely to consider the observed 45–49 age peak as an indicator of improved survival for PwMS in Greece. Furthermore, the nationwide availability of MRI during the last 25 years may have contributed to this finding.

The use of administrative data and registries rather than extrapolations from local medical records has led to a recent reconsideration of MS prevalence in many countries. The number of PwMS seems to be much higher than expected worldwide. In Italy, a recent study reported prevalence of MS 208.7 per 100,000 in 2017 in the region of Tuscany (34), using administrative data. A meta-analysis based on previously published relevant studies in Italy estimated current prevalence to 176 per 100,000 (35). In Norway, a nationwide study estimated a prevalence of 203 per 100,000 in 2012 (27). In the same year, using nationwide administrative data, prevalence of MS in France was upwards revised to 151.2 per 100,000 inhabitants, although researchers stated that at least 15% of the actual PwMS may have not been recorded (36). In Bavaria, Germany, prevalence was increased from 171 per 100,000 in 2006 to 277 per 100,000 in 2015, according to a study using health insurance data (24). In the United States, the use of health claims data has led to a reconsideration of MS prevalence which was estimated to be 309.2 per 100,000 in 2010 (37).

Onset of MS before the age of 18 varies between 2 and 4% depending on study (38). The age cutoff used for pediatric MS is the age of 16; however, the age 18 is also used by some researchers (39). The diagnosis of MS in youngsters is challenging since various conditions may present with similar clinical and radiological findings (40). The juvenile/adolescent cases identified in the current study are less than expected. This
finding may reflect the special precautions taken by physicians in order to set a definite MS diagnosis at young age. Moreover, 94.7% of PwMS under 18 years of age had received a DMD, but only rarely were they treated with drugs for symptomatic conditions, a finding that further underlines an overall reluctance of physicians to prescribe several types of medication in patients of this age group. In addition, further investigation is needed in order to explore whether access to specialized physicians is available for this specific population.

This study used prescription data of almost the entire Greek population, rather than extrapolating results from regional registries; thus, a more accurate MS prevalence in this country may have been estimated, at least with respect to adult PwMS. However, there is some weakness in our study for a number of reasons: Data about the level of disability, disease duration, and type could not be extracted. In addition, since no ICD-10 classification for clinically isolated syndrome (CIS) exists, people with CIS receiving DMDs may have been misclassified as PwMS. However, as the revisions of the McDonald criteria have enabled an earlier MS diagnosis and patients with a CIS diagnosis have substantially decreased, this discrepancy may have not significantly modified the estimated MS prevalence.

According to our study, 73.1% of the studied population has received a DMD. This percentage may also be underestimated, although not to a major degree, since patients participating in pre-approval clinical trials have not been recorded as receiving a DMD. Moreover, a proportion of PwMS treated with intravenous monoclonal antibodies may have not been recorded as PwMS under DMD treatment, due to the exclusion of some national hospitals' in-house treatments from this prescription database. However, most of these cases were included on the basis of their prescriptions for symptomatic treatment. Nevertheless, the percentage of PwMS under DMD was estimated as particularly...
This finding could be attributed to the impact of long disease duration and aging in the accumulation of disability in MS and the higher prevalence of the progressive forms of the disease in this age group.

Various algorithms have been validated in order to identify MS cases using secondary administrative data (36, 37, 41–43). Due to the variations of health policies, prescription systems, and registries amongst countries, these algorithms are not universally applicable on all administrative datasets, apart from those that are validated. In Greece, the lack of a nationwide registry of hospital admissions and digital medical records renders the validation of such an algorithm challenging. Therefore, our study does not have the strength to explore data validity in a quality degree of a national registry.

Incidence estimates may better reflect differences in chronic disease rates (2); however, when a short time period is studied, incidence may be overestimated. Cases may be misclassified as new if no data regarding the previous years exist4. Given that the period studied was short, we did not proceed to the calculation of current incidence of MS.

In lack of a nationwide registry for MS, we hereby provide for the first time an estimation of the current prevalence of MS in Greece, on the basis of the national administrative database for drug prescription. Regional variations of the MS prevalence in Greece were elucidated, and these results underscore the need for a thorough evaluation of the underlying factors (genetic, environmental, etc.) that may account for the observed differences. In spite of the methodological limitations stemming from the use of administrative data, our results verify increased MS prevalence, relatively to previous reports, in accordance to observations also made for other European populations. Moreover, the results of the present study point toward specific needs for optimization of the allocation of resources regarding MS in Greece and highlight the necessity of a national registry for PwMS that will include detailed and validated physician-reported clinical parameters. A nationwide registry for PwMS is currently under construction and is about to run a pilot phase soon. This registry is expected to enable further investigation of the regional MS prevalence heterogeneity with regards to genetic variances and access to healthcare.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this article are not readily available because raw data used in this study are property of the Greek Ministry of Health. Requests to access the datasets should be directed to https://www.moh.gov.gr/.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Ministry of Health, Greece. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

CB, EG, GP, DK, and NG: study concept, design, and supervision. CB, EG, MB, and IN: acquisition of data. CB, SS, TM, and DTsak: extraction of data and statistical analysis. EK, CB, EG, NG, ET, CP, and DTsal: analysis and interpretation. CB, EG, and MB: drafting of the manuscript. All co-authors: critical revision of the manuscript for important intellectual content and final approval of the version.

**ACKNOWLEDGMENTS**

The authors would like to thank Konstantinos Mathioudakis and Anastasios Tsolakidis, members of IDIKA S.A., for their invaluable help in data handling and Aliki Vrieniou on behalf of the Helenic Federation of Persons with Multiple Sclerosis for the thorough discussions over the MS prevalence parameters of the current study. Figure 2 was created with mapchart.net; compass image was downloaded from clker.com.

**REFERENCES**

1. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV et al. Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. Neurology. (2014) 83:1022–4. doi: 10.1212/WNL.0000000000000768

2. Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. *Lancet Neurol.* (2010) 9:520–32. doi: 10.1016/S1474-4422(10)70064-8

3. GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* (2019) 18:269–85. doi: 10.1016/S1474-4422(18)30443-5

4. Fromont A, Binquet C, Sauleau EA, Fournel I, Bellisario A, Adnet J, et al. Geographic variations of multiple sclerosis in France. *Brain.* (2010) 133(Pt 7):1889–99. doi: 10.1093/brain/awq134

5. Pivot D, Debouverie M, Grzebyk M. Geographical heterogeneity of multiple sclerosis prevalence in France. *PLoS ONE.* (2016) 11: e0167556. doi: 10.1371/journal.pone.0167556

6. Vasilopoulos D. Epidemiological data for multiple sclerosis in Greece. *Neuropediatrics.* (1984) 5:32–6. doi: 10.1159/00010841

7. Milonas I, Tsounis S, Logothetis I. Epidemiology of multiple sclerosis in northern Greece. *Acta Neurol Scand.* (1990) 81:43–7. doi: 10.1111/j.1600-0404.1990.tb0929.x
8. Piperidou HN, Heliopoulos IN, Maltezos ES, Milonas IA. Epidemiological data of multiple sclerosis in the province of Evros, Greece. Eur Neurol. (2003) 49:8–12. doi: 10.1159/000067020

9. Paphanatasopoulos P, Gourzoulidou E, Messinis L, Georgiou V, Leotsinidis M. Prevalence and incidence of multiple sclerosis in western Greece: a 23-year survey. Neuropediatrics. (2008) 39:167–73. doi: 10.1159/000122334

10. Kotzamanis D, Panou T, Mastorodemos V, Tzagournissakis M, Nikolakaki H, Sapanaki C, et al. Rising incidence of multiple sclerosis in females associated with urbanization. Neurology. (2012) 78:1728–35. doi: 10.1212/WNL.0b1013e3182530a09

11. Bezzi D, Battaglia MA. Multiple sclerosis epidemiology in Europe. Adv Exp Med Biol. (2017) 958:141–59. doi: 10.1007/978-3-319-47861-6_9

12. Flachenecker P, Buckow K, Puglatti M, Kés VB, Battaglia MA, Boyko A, et al. Multiple sclerosis registries in Europe - results of a systematic review. Mult Scler. (2014) 20:1523–32. doi: 10.1177/1352458514528760

13. Ward MMJ. Estimating disease prevalence and incidence using administrative data: some assembly required. Rheumatol. (2013) 40:1241–3. doi: 10.3899/rheum.130675

14. Thompson A, Banwell B, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances? J Neurol. (2017) 264:1185–92. doi: 10.1007/s10072-017-2801-9

15. Brownlee WJ, Swanton JK, Altmann DR, Ciccarelli O, Miller DH. Multiple sclerosis prevalence in Bavaria from 2006 to 2015. Mult Scler. (2018) 24:830–8. doi: 10.1177/1352458518790746

16. Kingwell E, Marriott JJ, Jetté N, Pringsheim T, Makhani N, Morrow SA, et al. Multiple sclerosis prevalence among Iranian population. Iran J Public Health. (2018) 47:e12856. doi: 10.1097/MD.0000000000012856

17. Schwenkenbecher P, Wurster U, Konen FF, Gicine S, Suh KW, Watjtes P, et al. Impact of the McDonald criteria 2017 on early diagnosis of multiple sclerosis: a population-based estimate using health claims data. BMC Neurol. (2020) 18:319. doi: 10.1186/s12883-018-1026-3

18. Dehghani R, Yunesian M, Sahraian MA, Gilasini HR, Kazemi Moghadam H, et al. Rising incidence of multiple sclerosis in Iran: a population-based estimate using health claims data. BMC Neurol. (2018) 18:27. doi: 10.1186/s12883-018-1029-6

19. Bezzini D, Battaglia MA. Estimated prevalence of multiple sclerosis in Italy in 2017. Mult Scler Relat Disord. (2019) 25:867–70. doi: 10.1016/j.msard.2019.03.008

20. Marrie RA, Yu N, Blanchard J, Leung S, Elliott L. The prevalence of MS in Canada: a population-based estimate using health claims data. J Neurol Neurosurg Psychiatry. (2001) 74:8–12. doi: 10.1136/jnnp-2001-218508

21. Troxell RM, Christy A. Atypical pediatric demyelinating diseases of the central nervous system. Curr Neurol Neurosci Rep. (2019) 19:95. doi: 10.1007/s11910-019-1015-9

22. Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. (2019) 92: e1029–40. doi: 10.1212/WNL.0000000000007035

23. Widdifield J, Ivers NM, Young J. Development and validation of a population-based, Germany-wide study of incident multiple sclerosis. Mult Scler. (2019) 25:871–9. doi: 10.1177/1352458519869190

24. Foulon S, Maura G, Dalichampt M, Alla F, Debovere M, Moreau T, et al. Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data. J Neurol. (2017) 264:1185–92. doi: 10.1007/s00415-017-8513-0

25. Hallin MT, Culppepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. (2019) 92: e1029–40. doi: 10.1212/WNL.0000000000007035

26. Battaglia MA, Bezzini D. Estimated prevalence of multiple sclerosis in Italy in 2015. Neurol Sci. (2017) 38:473–9. doi: 10.1007/s10072-016-2801-9

27. Wallin MT, Culppepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. (2019) 92: e1029–40. doi: 10.1212/WNL.0000000000007035

28. Köch-Henriksen N, Sorensen PS. Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere? Neurosci. (2011) 15:311–58. doi: 10.1016/j.jns.2011.09.003

29. Bezzini D, Battaglia MA. Multiple sclerosis epidemiology in Europe. Adv Exp Med Biol. (2017) 958:141–59. doi: 10.1007/978-3-319-47861-6_9

30. Bezzini D, Battaglia MA. Multiple sclerosis epidemiology in Europe. Adv Exp Med Biol. (2017) 958:141–59. doi: 10.1007/978-3-319-47861-6_9

31. Bakirtzis, Grigoriadou, Boziki, Kesidou, Siafis, Moysiadis, Tsakona, Thireos, Nikolaidis, Pourzitaki, Kouvelas, Papaziolis, Tsalikakis and others. Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Bakirtzis, Grigoriadou, Boziki, Kesidou, Siafis, Moysiadis, Tsakona, Thireos, Nikolaidis, Pourzitaki, Kouvelas, Papaziolis, Tsalikakis and Grigoriadis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.